Results 101 to 110 of about 45,696 (262)

Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria

Фармакоэкономика, 2019
Aim: to assess the economic outcomes of using ceftazidime + avibactam (compared with the recommended treatments) in adult patients with sepsis caused by carbapenem-resistant enterobacteria.Methods.
S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova   +3 more
doaj   +1 more source

An Unusual Case of Citrobacter koseri Infection During Pregnancy at 27 Weeks: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Early prenatal screening at 26 + 6 weeks detected Citrobacter koseri vaginal colonization in an asymptomatic high‐risk gravida. Culture‐guided IV ceftazidime (susceptible per CLSI testing) eradicated the pathogen without maternal/fetal compromise.
Mario Assenza, Michele Caramia, Jacopo Wabersich   +2 more
wiley   +1 more source

Evolution of ceftazidime–avibactam resistance driven by mutations in double-copy blaKPC-2 to blaKPC-189 during treatment of ST11 carbapenem-resistant Klebsiella pneumoniae

mSystems
Klebsiella pneumoniae carbapenemase (KPC) variants can contribute to resistance to ceftazidime–avibactam (CZA) in Klebsiella pneumoniae (KP). However, two-copy KPC variant-mediated resistance to CZA has rarely been reported to date.
Xiaofan Zhang, Yinrong Xie, Ying Zhang, Tailong Lei, Longjie Zhou, Jiayao Yao, Lin Liu, Haiyang Liu, Jintao He, Yunsong Yu, Yuexing Tu, Xi Li   +11 more
semanticscholar   +1 more source

Clinical Outcome Associated With Beta‐Lactam Allergy Labels in Hospitalized Patients in Belgium

Clinical and Translational Allergy, Volume 16, Issue 4, April 2026.
ABSTRACT Background In the United States, beta‐lactam allergy labels (BLAL) are documented in 9%–16% of hospitalized patients and associated with worse clinical outcomes such as increased mortality, length of hospital stay (LOS), intensive care unit (ICU) admission, and use of alternative antibiotics, providing an incentive for broad delabeling ...
Liesbeth Gilissen, Greet Van De Sijpe, Annouschka Laenen, Peter Declercq, Dries Wets, Ileana Ghiordanescu, Anca Mirela Chiriac, Willy E. Peetermans, Paul De Munter, Isabel Spriet, Rik Schrijvers   +10 more
wiley   +1 more source

Resistance to ceftazidime–avibactam and other new β-lactams in Pseudomonas aeruginosa clinical isolates: a multi-center surveillance study

Microbiology spectrum
New β-lactam–β-lactamase inhibitor combinations represent last-resort antibiotics to treat infections caused by multidrug-resistant Pseudomonas aeruginosa.
Felice Valzano, G. La Bella, T. Lopizzo, Anna Curci, L. Lupo, Elisabetta Morelli, A. Mosca, Marianna Marangi, Raffaela Melfitano, Tiziana Rollo, Rosella De Nittis, Fabio Arena   +11 more
semanticscholar   +1 more source

Microbial Etiology and Antimicrobial Resistance in Pneumonia Among Hospitalized Patients in Kazakhstan: A Systematic Review and Single‐Arm Meta‐Analysis of Prevalence Data

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov, Maxim Solomadin, Alyona Lavrinenko, Vyacheslav Beloussov, Vitaliy Strochkov, Shynggys Orkara, Nurlan Sandybayev, Sergey Yegorov   +7 more
wiley   +1 more source

Successful treatment of KPC-MDR septic shock with ceftazidime-avibactam in a pediatric critically ill patient

IDCases, 2019
Ceftazidime–avibactam is a combination agent consisting of the β-lactamase inhibitor avibactam and the broad-spectrum cephalosporin ceftazidime. There are no published case reports or studies evaluating the use of CAZ-AVI in pediatric critically ill ...
Maria Vargas, Antonio Riccardo Buonomo, Pasquale Buonanno, Carmine Iacovazzo, Giuseppe Servillo   +4 more
doaj   +1 more source

The Evaluation of Machine Learning Models Using Matrix‐Assisted Laser Desorption/Ionization Time‐of‐Flight Mass Spectrometry (MALDI–TOF–MS) Spectra for the Prediction of Antibiotic Resistance in Klebsiella pneumoniae

MicrobiologyOpen, Volume 15, Issue 2, April 2026.
Machine learning models developed from matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry spectra can rapidly predict antimicrobial resistance in Klebsiella pneumoniae. By transforming routine spectral data into accurate resistance profiles within minutes, this approach could reduce diagnostic delays and support earlier ...
Stephen Mark Edward Fordham
wiley   +1 more source

Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185

mBio
β-Lactamases can accumulate stepwise mutations that increase their resistance profiles to the latest β-lactam agents. CMY-185 is a CMY-2-like β-lactamase and was identified in an Escherichia coli clinical strain isolated from a patient who underwent ...
A. Kawai, W. C. Shropshire, Masahiro Suzuki, J. Borjan, S. Aitken, William C. Bachman, C. McElheny, Micah M. Bhatti, R. K. Shields, S. Shelburne, Y. Doi   +10 more
semanticscholar   +1 more source

In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing blaKPC or blaNDM

Infection and Drug Resistance, 2023
Junyang Kuai,1 Yawei Zhang,1 Binghuai Lu,2 Hongbin Chen,1 Yulin Zhang,2 Henan Li,1 Yuanyuan Wang,3 Qi Wang,1 Hui Wang,1 Xiaojuan Wang1 1Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, People’s Republic of China ...
Kuai J, Zhang Y, Lu B, Chen H, Zhang Y, Li H, Wang Y, Wang Q, Wang H, Wang X   +9 more
doaj